{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=52",
    "query": {
      "intervention": "Dose Level 3",
      "page": 52
    },
    "page_size": 10
  },
  "pagination": {
    "page": 52,
    "page_size": 10,
    "total_count": 17839,
    "total_pages": 1784,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=53&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+3&page=51&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T13:49:55.850Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04508647",
      "title": "Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Marginal Zone Lymphoma",
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "DRUG"
        },
        {
          "name": "Umbralisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2020-11-23",
      "completion_date": "2022-07-14",
      "has_results": true,
      "last_update_posted_date": "2024-03-21",
      "last_synced_at": "2026-11-18T13:49:55.850Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04508647"
    },
    {
      "nct_id": "NCT02508649",
      "title": "Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Septic Shock"
      ],
      "interventions": [
        {
          "name": "selepressin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 868,
      "start_date": "2015-07",
      "completion_date": "2018-02-26",
      "has_results": true,
      "last_update_posted_date": "2021-04-06",
      "last_synced_at": "2026-11-18T13:49:55.850Z",
      "location_count": 17,
      "location_summary": "Colorado Springs, Colorado • Idaho Falls, Idaho • Chicago, Illinois + 13 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02508649"
    },
    {
      "nct_id": "NCT04844749",
      "title": "Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer",
        "Androgen Resistant Prostatic Cancer"
      ],
      "interventions": [
        {
          "name": "VERU-111",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide, Abiraterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veru Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 105,
      "start_date": "2021-06-24",
      "completion_date": "2023-05-04",
      "has_results": false,
      "last_update_posted_date": "2024-02-05",
      "last_synced_at": "2026-11-18T13:49:55.850Z",
      "location_count": 40,
      "location_summary": "Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 36 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04844749"
    },
    {
      "nct_id": "NCT04180215",
      "title": "A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HPV-Related Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "HB-201 intravenous administration.",
          "type": "DRUG"
        },
        {
          "name": "HB-202 intravenous administration alternating with HB-201 intravenous administration.",
          "type": "DRUG"
        },
        {
          "name": "HB-201 intravenous administration + standard of care regimen including pembrolizumab.",
          "type": "DRUG"
        },
        {
          "name": "HB-202 / HB-201 alternating intravenous administration + pembrolizumab.",
          "type": "DRUG"
        },
        {
          "name": "HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.",
          "type": "DRUG"
        },
        {
          "name": "HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hookipa Biotech GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 198,
      "start_date": "2019-12-11",
      "completion_date": "2025-01-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-11-18T13:49:55.850Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Fayetteville, Arkansas + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04180215"
    },
    {
      "nct_id": "NCT06585774",
      "title": "A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Graft-versus-host-disease"
      ],
      "interventions": [
        {
          "name": "INCA034176",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2025-01-21",
      "completion_date": "2030-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-18T13:49:55.850Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06585774"
    },
    {
      "nct_id": "NCT01730118",
      "title": "Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "Adenocarcinomas",
        "Metastatic Solid Tumors Characterized by HER2/Neu Expression"
      ],
      "interventions": [
        {
          "name": "Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2013-03-04",
      "completion_date": "2019-12-03",
      "has_results": true,
      "last_update_posted_date": "2022-09-10",
      "last_synced_at": "2026-11-18T13:49:55.850Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01730118"
    },
    {
      "nct_id": "NCT03973918",
      "title": "Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade Glioma",
        "BRAF V600E",
        "BRAF V600K",
        "Anaplastic Astrocytoma",
        "Anaplastic Pleomorphic Xanthoastrocytoma",
        "Gliosarcoma",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Encorafenib",
          "type": "DRUG"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Research Bloods",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tumor Tissue",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2019-07-29",
      "completion_date": "2023-10-01",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-11-18T13:49:55.850Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03973918"
    },
    {
      "nct_id": "NCT07043452",
      "title": "Measuring Acute Drug Demand in Humans II",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Blinded Study Medication - Condition 1",
          "type": "DRUG"
        },
        {
          "name": "Blinded Study Medication - Condition 2",
          "type": "DRUG"
        },
        {
          "name": "Blinded Study Medication - Condition 3",
          "type": "DRUG"
        },
        {
          "name": "Blinded Study Medication - Condition 4",
          "type": "DRUG"
        },
        {
          "name": "Blinded Study Medication - Condition 5",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-11-15",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-11-18T13:49:55.850Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07043452"
    },
    {
      "nct_id": "NCT00379938",
      "title": "B-19 Parvovirus Vaccine Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Parvovirus B19 Infection"
      ],
      "interventions": [
        {
          "name": "VAI-VP705 (parvovirus B-19 vaccine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "MF-59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 43,
      "start_date": "2006-08",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2011-08-15",
      "last_synced_at": "2026-11-18T13:49:55.850Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00379938"
    },
    {
      "nct_id": "NCT02683148",
      "title": "DHEA in Synovial Sarcoma Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Synovial Sarcoma",
        "Sarcoma, Synovial"
      ],
      "interventions": [
        {
          "name": "DHEA",
          "type": "DRUG"
        },
        {
          "name": "FACT-67 validated survey",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2016-09-13",
      "completion_date": "2019-04-04",
      "has_results": false,
      "last_update_posted_date": "2019-09-09",
      "last_synced_at": "2026-11-18T13:49:55.850Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02683148"
    }
  ]
}